Literature DB >> 6798925

Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

N Rastogi, C Frehel, A Ryter, H Ohayon, M Lesourd, H L David.   

Abstract

Whole cells of Mycobacterium avium, characterized by their negative response in the nine biochemical tests used for mycobacterial identification in our laboratory, turned positive for nitrate reductase, Tween-80 hydrolysis, beta-glucosidase, acid phosphatase, alkaline phosphatase, penicillinase, and trehalase after their wall portion was removed to yield spheroplasts. This suggested that the negative results in most of the biochemical procedures were caused by the exclusion mechanism at the wall level. Preliminary transmission and scanning electron microscopic studies showed differences at wall level between laboratory-maintained opaque, dome-shaped (SmD) and host-recycled smooth, transparent (SmT) colony type variants of M. avium and suggested the presence of an outer regularly structured layer in SmT variants. Comparative ultrastructural studies utilizing different polysaccharide coloration methods confirmed the presence of an outer polysaccharide layer in SmT variants which was probably related to their enhanced pathogenicity for experimental animals and drug resistance as compared to that of SmD variants. These findings are discussed with respect to multiple drug resistance, virulence, and gene expression of M. avium.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6798925      PMCID: PMC181770          DOI: 10.1128/AAC.20.5.666

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  57 in total

1.  Preparation of protoplasts and whole cell ghosts from Mycobacterium smegmatis.

Authors:  N Rastogi; T A Venkitasubramanian
Journal:  J Gen Microbiol       Date:  1979-12

2.  Studies on gonococcus infection. XIV. Cell wall protein differences among color/opacity colony variants of Neisseria gonorrhoeae.

Authors:  J Swanson
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

3.  Paired fibrous structure in mycobacteria.

Authors:  K TAKEYA; R MORI; M KOIKE; T TODA
Journal:  Biochim Biophys Acta       Date:  1958-10

4.  Humoral bactericidal systems: nonspecific and specific mechanisms.

Authors:  R C Skarnes
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

5.  The nature of the electron-transparent zone that surrounds Mycobacterium lepraemurium inside host cells.

Authors:  P Draper; R J Rees
Journal:  J Gen Microbiol       Date:  1973-07

Review 6.  Bacterial exopolysaccharides.

Authors:  I W Sutherland
Journal:  Adv Microb Physiol       Date:  1972       Impact factor: 3.517

7.  Response of Mycobacterium avium to ultraviolet irradiation.

Authors:  C M McCarthy; J O Schaefer
Journal:  Appl Microbiol       Date:  1974-07

8.  Spheroplast induction and lysis of BCG strains by glycine and lysozyme.

Authors:  H Sato; B B Diena; L Greenberg
Journal:  Can J Microbiol       Date:  1966-04       Impact factor: 2.419

9.  Spontaneous and Induced Mutation in Mycobacterium avium.

Authors:  C McCarthy
Journal:  Infect Immun       Date:  1970-09       Impact factor: 3.441

10.  NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION.

Authors:  D S KELLOGG; W L PEACOCK; W E DEACON; L BROWN; D I PIRKLE
Journal:  J Bacteriol       Date:  1963-06       Impact factor: 3.490

View more
  60 in total

1.  Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.

Authors:  S Majumdar; D Flasher; D S Friend; P Nassos; D Yajko; W K Hadley; N Düzgüneş
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Authors:  U Hjelm; J Kaustová; M Kubín; S E Hoffner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

4.  Cell-free system responsible for internal radiolabeling of glycopeptidolipids of the Mycobacterium avium complex.

Authors:  N Ramasesh; E L Wright; W W Barrow
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

5.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

6.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease.

Authors:  R J Chiodini; H J Van Kruiningen; W R Thayer; J A Coutu
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

8.  Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

Authors:  N Rastogi; K S Goh; V Labrousse
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

9.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.